|
|
Survival
of glioma patients after complementary treatment with galactoside-specific
lectin from mistletoe
Lenartz D,
Dott U, Menzel J, Schierholz JM, Beuth J
Stadtische
Kliniken, Department of Neurosurgery, Cologne, Germany
Malignant
glioma patients were prospectively enrolled into a clinical trial.
All the patients were provided with the internationally recommended oncologic
standard treatment (neurosurgery, radiation, basic clinical care according to
protocol and indication) and randomly divided into a treatment group (receiving
complementary immunotherapy with a galactoside-specific lectin from mistletoe,
ML-1) and a control group (without additional complementary treatment).
Whereas the beneficial effects of ML-1 treatment on immunological rescue and
quality of life have been recently shown, evaluation of relapse free/overall
survival was performed after a 50 months follow up time.
Non-stratified analysis of all the patients revealed non-relevant prolongation
of relapse-free intervals/overall survival time for the treatment group.
However, analysis of stratified stage III/IV glioma patients demonstrated:
1. a tendency for a prolongation of relapse-free survival for patients of the
treatment group (17.43 +/- 8.2 months) vs. the control group (10.45 +/- 3.9
months)
2. a statistically significant (BRESLOW p = 0.035) prolongation of the overall
survival for the treatment group (20.05 +/- 3.5 months) as compared to the
control group (9.90 +/- 2.1 months).
These promising data warrant confirmation in a GCP-based prospectively
randomized (multicenter) study, which is currently under consideration.
PMID:
10928154 [PubMed - indexed for MEDLINE]
Source:
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=10928154&dopt=Abstract
|
